Skip to site menu Skip to page content

Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes
Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

  • Gain a competitive edge
  • Enhance your sales strategy
  • Get forward-looking insights
  • Support your decision making
GlobalData

Buy Now
Data Insights

(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)